FindTrial
Sign In

The clinical research on the Alzheimer's disease with extracts from the Chinese medicine compound based on the pathogenesis of 'deficiency, stasis and toxin'

The clinical research on the Alzheimer's disease with extracts from the Chinese medicine compound based on the pathogenesis of 'deficiency, stasis and toxin'

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17011746
Enrollment
Unknown
Registered
2017-06-22
Start date
2015-06-30
Completion date
Unknown
Last updated
2017-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer’s disease

Interventions

Huannao YicongFang group:Huannao Yicong decoction + Placebo of Donepezil
Control group:Donepezil once a day + Placebo of Huannao icong decoction

Sponsors

Xiyuan Hospital, China Academy of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: National Institute of Aging Alzheimer's Association diagnostic guidelines (NIN-AA,2011) Guidelines for the treatment of senile dementia by traditional Chinese medicine, issued by the Ministry of Health(2002).

Exclusion criteria

Exclusion criteria: Exclusion the following disease, including sencephalitis, epilepsy, Parkinson's disease, trauma, or other diseases cause of dementia and severe liver and kidney system disease.

Design outcomes

Primary

MeasureTime frame
Serum acetylcholinesterase;Serum acetylcholinesterase;Neuropsychological scale,;—

Countries

China

Contacts

Public ContactHao Li

Xiyuan Hospital, China Academy of Traditional Chinese Medicine

xyhplihao1965@126.com+86 010-62835088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 5, 2026